Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Total raised

$52M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2026